Global Drug-eluting Balloon Catheters Market Size study & Forecast, by Drug (Paclitaxel, Sirolimus, Others) by Indication (Coronary Intervention, Peripheral Intervention), by End-user (Hospitals & ASCs, Specialty Clinics and Catheterization Laboratories)

Global Drug-eluting Balloon Catheters Market Size study & Forecast, by Drug (Paclitaxel, Sirolimus, Others) by Indication (Coronary Intervention, Peripheral Intervention), by End-user (Hospitals & ASCs, Specialty Clinics and Catheterization Laboratories) and Regional Analysis, 2022-2029

Global Drug-eluting Balloon Catheters Market is valued at approximately USD 529.4 million in 2021 and is anticipated to grow with a healthy growth rate of more than 8.9% over the forecast period 2022-2029. Drug-eluting balloon catheters also generally named drug-coated balloon catheters are semi-compliant angioplasty balloons used to deliver anti-proliferative drugs via inflated balloons. It helps in eluting the drug in the targeted vessel and lessens the negative impact of late thrombosis without implanting a permanent foreign object. The balloon technology is based on the theory of targeted medication delivery, which promotes quick artery wall repair and inhibits the growth of smooth muscle cells. The global market growth is likely to be driven by the factors such as increasing cases of peripheral and coronary artery diseases, the growing geriatric population leading to cardiovascular diseases, coupled with the rising need for surgical interventions.

Surging demand for minimally invasive procedures is acting as a catalyzing factor in the market growth across the globe. For instance, as per the NEWS Medical Life Sciences article released in December 2021, drug-coated balloon catheters are highly used with minimally invasive procedures and gaining high traction as replacements over dangerous stent treatment the myocardial infarction. Similarly, according to the NCBI article released in February 2021, the drug-coated balloon offers a wide range of benefits such as minimal side effects than drug-eluting stents, which creates it as a most adaptive therapeutics approach for coronary disease. Accordingly, the high preference towards minimally invasive procedures owing to its leads surgeries less painful and helps in fast recovery. Moreover, the rising introduction of paclitaxel-coated balloon catheter products, as well as the increasing technological advancements in drug-eluting balloon catheters are presenting various lucrative opportunities over the forecasting years.
However, the high cost of development and commercialization of drug-eluting balloons, along with the adverse effects and product recalls are challenging the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Drug-eluting Balloon Catheters Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the rising incidences of heart diseases and the availability of advanced healthcare facilities. Whereas, the Asia Pacific is also expected to grow with the highest CAGR during the forecast period. Factors such as the rising prevalence of peripheral artery disease, growing patient population, as well as increasing preference for minimally invasive procedures are propelling the demand for drug-eluting balloon catheters in the market space.

Major market players included in this report are:
Medtronic Plc
Koninklijke Philips N.V.
Boston Scientific Corporation
BD (Becton, Dickinson and Company)
B. Braun SE
Meril Life Sciences Pvt. Ltd.
BIOTRONIK
Cordis Corporation
MicroPort Medical (Group) Co., Ltd.
Terumo Corporation

Recent Developments in the Market:
 In August 2022, BD unveiled the introduction of the first-in-human prevision trial to assess the safety and effectiveness of the peripheral sirolimus drug-coated balloon (DCB). The purpose of the trials was to evaluate sirolimus' efficacy as a future therapy option for people with peripheral artery disease (PAD).
 In January 2021, MicroPort Medical (Group) Co., Ltd. announced that they received an EU CE mark for their Reewarm PTX Drug Coated Balloon PTA catheter for femoral popliteal artery indication during percutaneous transluminal angioplasty.
 In November 2020, Boston Scientific Corporation declared that the Ranger, a drug-eluting balloon catheter received approval from U.S. Food & Drug Administration (FDA). The product is specially designed to treat patients with PAD, Proximal Popliteal Artery (PPA),a dn Superficial Femoral Artery (SFA).

Global Drug-eluting Balloon Catheters Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug, Indication, End-user, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below:

By Drug:
Paclitaxel
Sirolimus
Others
By Indication:
Coronary Intervention
Peripheral Intervention
By End-user:
Hospitals & ASCs
Specialty Clinics and Catheterization Laboratories
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World



Companies Mentioned

Medtronic Plc
Koninklijke Philips N.V.
Boston Scientific Corporation
BD (Becton, Dickinson and Company)
B. Braun SE
Meril Life Sciences Pvt. Ltd.
BIOTRONIK
Cordis Corporation
MicroPort Medical (Group) Co., Ltd.
Terumo Corporation

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.